JOURNAL OF HEPATOLOGY, published by Elsevier, stands as a preeminent source in the field of Hepatology, with its impact underscored by a remarkable 2023 Category Quartile of Q1 and a Scopus rank of 3rd out of 82 journals, placing it in the 96th percentile for the discipline. Since its inception in 1985, this journal has been a vital conduit for the dissemination of pioneering research, clinical studies, and reviews related to liver diseases and their impact on global health. Although it currently does not offer open access options, the journal is committed to providing top-tier content to its readership—researchers, medical professionals, and students—in order to advance knowledge and foster innovation in hepatology. With a broad and inclusive scope, it aims to cover significant breakthroughs, therapeutic advancements, and epidemiological studies, continually pushing the boundaries of understanding in liver health. The journal is based in Amsterdam, Netherlands, and remains an essential resource for those dedicated to the progression of hepatologic science.

Annals of Hepatology is an esteemed open-access journal dedicated to the dynamic field of liver research and hepatology. Published by Elsevier España since 2002, this journal has established itself as a pivotal resource for researchers and clinicians alike, boasting a remarkable impact in the medical community with its 2023 rankings placing it in the Q2 quartile for Hepatology and Q1 quartile in Medicine (Miscellaneous). With an impressive Scopus rank of #20 out of 82 in the field of Hepatology and a notable 76th percentile standing, the journal is committed to disseminating high-quality, peer-reviewed articles that advance the understanding of liver diseases and their management. The editorial scope encompasses a broad range of topics, including liver pathology, therapeutic interventions, and public health implications related to hepatic disorders. Researchers, healthcare professionals, and students interested in the latest advancements in hepatology will find Annals of Hepatology an invaluable platform for sharing and accessing knowledge, with the convenience of open access enhancing global visibility and collaboration in this critical field of medicine.

Gastroenterologia y Hepatologia, published by Elsevier España SLU, is a distinguished journal dedicated to advancing the fields of gastroenterology and hepatology. With a publication history spanning from 1982 to 2024, this journal is recognized for its commitment to disseminating high-quality research and reviews that address critical developments in the diagnosis and treatment of gastrointestinal and liver diseases. Although it currently ranks in the Q3 quartile in both gastroenterology and hepatology based on the 2023 metrics, the journal continues to attract a global audience of researchers, healthcare professionals, and students eager to engage with the latest findings. The journal is accessible in both print and electronic formats (ISSN: 0210-5705), making its valuable insights reachable to a broad spectrum of subscribers. By fostering a platform for rigorous scholarly communication, Gastroenterologia y Hepatologia plays a vital role in shaping the future of research in these essential medical fields.

Clinics in Liver Disease is an esteemed peer-reviewed journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of hepatology. Established in 1997 and covering a broad range of topics within liver disease research, this journal serves as a vital resource for researchers, clinicians, and students engaged in the study of liver health and diseases. With a commendable impact factor placing it within the Q2 category in Hepatology and ranking #32 out of 82 in the Scopus classifications, it consistently disseminates high-quality research and clinical insights. The journal’s commitment to promoting understanding and management of liver diseases is reflected in its rigorous editorial standards and comprehensive review processes. Although not an open-access publication, Clinics in Liver Disease offers subscription options that ensure accessibility to up-to-date research and reviews critical for both academic and clinical success.

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

The JOURNAL OF VIRAL HEPATITIS, published by WILEY, is a leading international journal dedicated to the dissemination of cutting-edge research in the fields of hepatology, infectious diseases, and virology. Established in 1994, this esteemed journal has created a significant impact within the scientific community, reflected by its ranking in the Q1 category for infectious diseases and Q2 for both hepatology and virology in the most recent quartile rankings. The journal provides an essential platform for scholars and practitioners to share their findings on viral hepatitis, enhancing our understanding of its pathogenesis, epidemiology, and treatment options. With its impact factor reflecting a robust citation record, the JOURNAL OF VIRAL HEPATITIS remains indispensable for those engaged in research and clinical practice regarding viral hepatitic infections. Researchers can access the journal through traditional subscription routes, underlining its commitment to advancing knowledge and fostering collaboration among scientists worldwide. As it approaches its convergence with new findings and innovative methodologies by 2024, the journal looks forward to continuing its pivotal role in shaping the future of hepatology research.

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

AIDS Research and Therapy is a prestigious peer-reviewed journal dedicated to disseminating cutting-edge research in the fields of AIDS and HIV therapy. Published by BMC, this Open Access journal has been freely available since its inception in 2004, facilitating global access to vital research findings. Based in the United Kingdom, the journal covers a diverse range of topics including molecular medicine, pharmacology, and virology, making it a crucial resource for researchers and clinicians alike. Recognized for its strong impact within the scientific community, it holds a Q2 quartile ranking in multiple categories as of 2023, including Molecular Medicine and Pharmacology. With an aim to enhance understanding and improve clinical outcomes for those affected by HIV/AIDS, AIDS Research and Therapy serves as an essential platform for the exchange of innovative ideas and practices that can inform future therapies and interventions. Researchers, professionals, and students seeking high-quality, peer-reviewed content will find this journal invaluable in advancing their knowledge and efforts in combating the HIV/AIDS epidemic.

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.